|4Feb 4, 4:38 PM ET

Benchmark Capital Management Co. V, L.L.C. 4

4 · 1Life Healthcare Inc · Filed Feb 4, 2020

Insider Transaction Report

Form 4
Period: 2020-02-04
Transactions
  • Conversion

    Common Stock

    2020-02-04+679,39313,398,383 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2020-02-04+220,21713,618,600 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2020-02-04+3,046,16812,718,990 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2020-02-045,749,6300 total(indirect: See Footnote)
    Common Stock (5,749,630 underlying)
  • Conversion

    Series D Preferred Stock

    2020-02-043,046,1680 total(indirect: See Footnote)
    Common Stock (3,046,168 underlying)
  • Conversion

    Series E Preferred Stock

    2020-02-04679,3930 total(indirect: See Footnote)
    Common Stock (679,393 underlying)
  • Conversion

    Common Stock

    2020-02-04+5,749,6305,936,630 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2020-02-043,736,1920 total(indirect: See Footnote)
    Common Stock (3,736,192 underlying)
  • Conversion

    Common Stock

    2020-02-04+3,736,1929,672,822 total(indirect: See Footnote)
  • Conversion

    Series G Preferred Stock

    2020-02-04220,2170 total(indirect: See Footnote)
    Common Stock (220,217 underlying)
  • Conversion

    Warrant (Right to Buy)

    2020-02-0411,0100 total(indirect: See Footnote)
    Exercise: $6.59Exp: 2020-10-03Series G Preferred Stock (11,010 underlying)
  • Conversion

    Warrant (Right to Buy)

    2020-02-04+11,01011,010 total(indirect: See Footnote)
    Exercise: $6.59Exp: 2020-10-03Common Stock (11,010 underlying)
Footnotes (3)
  • [F1]Each share of Issuer's Preferred Stock automatically converted into an equal number of shares of Issuer's Common Stock upon the closing of the Issuer's initial public offering and has no expiration date.
  • [F2]Securities held by Benchmark Capital Partners V, L.P. ("BCP V"), as nominee for BCP V, Benchmark Founders' Fund V, L.P. ("BFF V"), Benchmark Founders' Fund V-A, L.P. ("BFF V-A"), Benchmark Founders' Fund V-B, L.P. ("BFF V-B"), and related individuals. Benchmark Capital Management Co. V, L.L.C. ("BCMC V"), the general partner of BCP V, BFF V, BFF V-A and BFF V-B, may be deemed to have sole voting and dispositive power over the securities. Bruce W. Dunlevie, a member of the Issuer's board of directors, Alexandre Balkanski, Peter H. Fenton, J. William Gurley, Kevin R. Harvey, Robert C. Kagle, Mitchell H. Lasky and Steven M. Spurlock are the managing members of BCMC V, and each of them may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims the existence of a "group" and disclaims beneficial ownership of the securities, except to the extent of such person or entity's pecuniary interest in such securities.
  • [F3]Shares subject to the warrant are immediately exercisable.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION